FindTrial
Sign In

A database study to understand the current treatment patterns and efficacy of high-dose methotrexate-based therapy in Japanese patients with Primary central nervous system lymphoma

A database study to understand the current treatment patterns and efficacy of high-dose methotrexate-based therapy in Japanese patients with Primary central nervous system lymphoma - A database study to understand the current treatment patterns and efficacy of high-dose methotrexate-based therapy in Japanese patients with PCNSL

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042120
Enrollment
Unknown
Registered
2020-10-14
Start date
2020-10-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma

Interventions

None listed

Sponsors

Ono Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Have a prescription record of HD-MTX - Age 20 years or more on the day of the index etc.

Exclusion criteria

Exclusion criteria: - Patients whose data period before the index is less than 6 months (183 days) - Patients with a follow-up period of less than 12 months (365 days) - Patients with a cancer recurrence flag on the initial hospitalization record etc.

Design outcomes

Primary

MeasureTime frame
Treatment-free period from HD-MTX -based therapy to retreatment with HD-MTX -based therapy—

Countries

Japan

Contacts

Public ContactIchiro Matsumoto

Ono Pharmaceutical Co., Ltd. Oncology Medical Affairs

ic.matsumoto@ono-pharma.com03-5640-3701

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026